Innovent and Bolt reached an agreement to jointly develop three anti-tumor drugs using antibody-immune stimulation coupling technology

August 27, 2021, San Francisco, USA and Suzhou, China-Cinda Biopharmaceutical Group (Hong Kong Stock Exchange stock code: 01801), a company dedicated to R&D, production and sales of major cancers, metabolic diseases, autoimmunity, etc.

Through this research and development cooperation, Innovent will use its proprietary antibody drug portfolio and undisclosed tumor target research and development capabilities, combined with Bolt’s advanced antibody-immunostimulatory conjugate (ISAC) technology and myeloid cell expertise.

According to the terms of the agreement, Cinda Bio will have the rights to the Greater China region of the three cooperative projects, while retaining the global rights of one of the projects and the right to choose the rights of the other project in regions other than North America

Dr.

Bolt Biotherapeutics, Inc.

About Cinda Bio

"Starting from the letter, reaching the line", to develop high-quality biological drugs that the common people can afford is the ideal and goal of Cinda Bio

Since its establishment, the company has stood out among many biopharmaceutical companies with its innovative achievements and international operating model

Cinda Bio has established an internationally advanced high-end biopharmaceutical development and industrialization talent team, including many returned experts, and has cooperated with international partners such as Eli Lilly, Adimab, Incyte, MD Anderson Cancer Center and Hanmi of South Korea.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc.

Forward-looking statement

The information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made